Market Overview

Jim Cramer: Wall Street Analysts Are Missing Snap's One True Advantage

Jim Cramer: Wall Street Analysts Are Missing Snap's One True Advantage

According to CNBC's Jim Cramer, nearly every Wall Street analyst failed to talk about Snap Inc (NYSE: SNAP)'s one major advantage that no other social media platform has yet to copy: the ability for kids to communicate without their parents monitoring their activity.

Cramer explained during CNBC's "Squawk on the Street" segment on Tuesday that the problem with Snap's whole appeal is two-fold. First, iconic household names such as Procter & Gamble Co (NYSE: PG) may not want their brands associated with some of the content that kids are secretly sharing among each other.

Second, whatever advantage Snap holds in the social media landscape can be copied by Facebook Inc (NASDAQ: FB)'s CEO Mark Zuckerberg. In fact, Cramer said the Facebook co-founder is the "most competitive CEO" to lead a company since Larry Ellison.

Facebook Launches 'Snap Two'

Cramer further suggested that Facebook's new feature announcement on Tuesday is essentially "Snap Two." Masks, frames and interactive filters have long been a hallmark of Snapchat, but that is no longer the case and Snap's 4 percent decline on Tuesday, despite some support from Wall Street analysts earlier in the day, is showing how investors really feel about Zuckerberg's ambitions to take away all of Snap's advantages.

"I'm telling you this guy [Zuckerberg] does not like anybody encroaching on his turf," Cramer emphasized.

Related Links:

How Facebook Is Laying Siege To Snapchat

6 Biggest Takeaways From Zuckerberg's 6,000 Word Facebook Manifesto

Posted-In: CNBC Jim Cramer Mark Zuckerberg SnapChat social media Jim CramerTech Media Best of Benzinga


Related Articles (PG + FB)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial
Book A Demo
Learn How You Can Succeed In The Market With Benzinga Pro

Fastest Market News

Real-Time News Alerts

Customizable News Filters

Book A Demo

Regeneron's Dupixent Passes The FDA Muster; Baird Sees Strong Launch

Quietly, This Tiger ETF Rises Again